NCT06134765View on ClinicalTrials.gov

Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

March 30, 2025

Conditions
Colorectal CancerPancreatic Cancer
Interventions
DRUG

Bemalenograstim alfa

Bemalenograstim alfa,20mg, once every treatment

Trial Locations (1)

Unknown

the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06134765 - Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | Biotech Hunter | Biotech Hunter